In recent years, significant development in the treatment of prostate cancer has taken place. One of the most documented methods of treatment in patients characterised by a high risk of progression is a combination of radiotherapy (RT) with long-term hormone therapy (HT).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
In this group of patients, neither RT alone nor HT alone allows satisfactory outcomes to be achieved, and therefore as monotherapy they are not recommended as optimal methods of treatment In this review, we summarise arguments for combining radiotherapy with hormonal therapy in high-risk prostate cancer, with an emphasis on the results of phase III trials
Contemporary oncology (Poznań, Poland) 2015 Mar 26 [Epub]
Tomasz Milecki, Andrzej Antczak, Zbigniew Kwias, Piotr Milecki
Department and Clinic of Urology and Urologic Oncology, Poznan University of Medical Science, Poznan, Poland , Department and Clinic of Urology and Urologic Oncology, Poznan University of Medical Science, Poznan, Poland , Department and Clinic of Urology and Urologic Oncology, Poznan University of Medical Science, Poznan, Poland , Chair and Department of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland ; Department of Radiotherapy, Greater Poland Cancer Centre, Poznan, Poland